• Thermal-Protective Hydrogel for Tumor Ablation

  2026-09-02

  The reference study develops an injectable MR@CaP@HA hydrogel that couples local thermal insulation with pH- and glutathione-responsive delivery of mitoxantrone and Resiquimod (R-848). In an ablation model, this integrated design protected nearby tissue, enhanced immunogenic tumor killing, promoted dendritic-cell and macrophage activation, and produced complete tumor eradication in a subset of animals.

• Rotigotine’s Antidepressant Effects in Rat Models

  2026-09-02

  This 2006 study evaluated rotigotine across several rat models to distinguish antidepressant-like activity from nonspecific changes in locomotion. Its central finding was that repeated low-dose treatment improved learned-helplessness behavior, while higher-dose effects were harder to interpret because rotigotine also increased spontaneous motor activity.

• Phosphatase Inhibitor Cocktail 2 for Stress-Liver Signaling

  2026-09-01

  Phosphatase Inhibitor Cocktail 2 supports protein phosphorylation preservation in stress-response and liver injury assays. This guide connects phosphatase control with the CerS6–ceramide–AMPK/p38 pathway and provides a practical framework for selecting controls, handling extracts, and interpreting phosphoprotein data.

• Acetylcysteine: Redox and Mucus Research Guide

  2026-09-01

  Acetylcysteine, also called N-acetyl-L-cysteine (NAC), supplies cysteine for glutathione biosynthesis and can reduce mucoprotein disulfide bonds. This guide defines its redox, mucolytic, disease-model, and 3D tumor-stroma research uses while separating product specifications from evidence that does not directly test NAC.

• Dual Luciferase Reporter Gene System for Wnt Studies

  2026-08-31

  Use the Dual Luciferase Reporter Gene System to normalize promoter and pathway readouts within the same mammalian-cell sample, from CENPI-driven Wnt signaling experiments to scalable screening. This guide translates the 2025 breast cancer study into practical reporter design, workflow, and troubleshooting decisions.

• SMAD3 Inhibition, miRNA-140, and Early OA

  2026-08-31

  Xiang et al. investigated how SMAD3 inhibition affects the cartilage-degrading enzyme ADAMTS-5 during early osteoarthritis. Their in vitro and rat studies support a regulatory link between SMAD3, miRNA-140, and ADAMTS-5, identifying a molecular window in which pathway inhibition changes catabolic signaling before major cartilage-structure abnormalities become evident.

• P2RX1-Driven Mitochondrial Apoptosis in Ph+ ALL

  2026-08-30

  Li et al. identify P2RX1 as a regulator of tyrosine kinase inhibitor sensitivity in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking calcium/CaMKII activity to mitochondrial dysfunction and PI3K/Akt suppression. The findings provide a mechanistic framework for studying treatment-induced cell death while highlighting the need for validation in patient-derived and in vivo models.

• Bafilomycin A1 in Lysosomal Stress Assays

  2026-08-29

  Bafilomycin A1 is a reversible V-ATPase inhibitor that helps separate lysosomal acidification from metabolic-stress signaling. This guide translates recent AMPK-SQSTM1 research into practical assay design, controls, and interpretation strategies.

• Engineering Precision in CRISPR-Cas9 mRNA

  2026-08-28

  A mechanistic and translational analysis of how Cap1 capping, m1Ψ modification, poly(A) design, and Cas9 mRNA trafficking can shape CRISPR-Cas9 genome editing performance and specificity.

• CCR7–Notch1 Crosstalk Drives Mammary Cancer Stemness

  2026-08-28

  Boyle et al. show that CCR7 and Notch1 form a functional signaling circuit that maintains stem-like properties in MMTV-PyMT mammary cancer cells. The study supports a mechanistic rationale for dual pathway investigation, while its mouse-model and ex vivo design requires careful validation before clinical translation.

• Aurora Kinase A in High-Risk Retinoblastoma

  2026-08-27

  A 2024 study found that Aurora kinase A is overexpressed in human retinoblastoma and associated with histopathologic features linked to poor clinical risk. By combining patient-tissue analysis with genetic depletion, pharmacologic inhibition, patient-derived models, xenografts, and enucleated specimens, the investigators provide a strong preclinical rationale for evaluating Aurora A as a therapeutic target in advanced or chemotherapy-refractory disease.

• HRP Goat Anti-Mouse IgG (H+L) Antibody Guide

  2026-08-27

  HRP Goat Anti-Mouse IgG (H+L) Antibody, SKU K1221, provides an HRP-linked detection layer for mouse IgG primary antibodies in Western blotting, ELISA, IHC, and ICC. It should not be selected for non-mouse primary antibodies, direct primary-antibody detection, or workflows that require a fluorescent or otherwise non-HRP reporter.

• Danazol as a Causal Probe of Pubertal Timing

  2026-08-26

  Danazol is more than an androgenic steroid tool: it can function as a mechanistic perturbation for studying hypothalamic–pituitary–gonadal axis timing. This article interprets recent rat-model evidence and translates it into stronger assay design, controls, and translational decisions.

• Risedronate Sodium: Applied Research Workflows

  2026-08-26

  Risedronate Sodium combines osteoclast-directed pharmacology with emerging lung-targeted delivery strategies, making it useful for bone metabolism research, formulation development, and exploratory pulmonary assays. This practical guide covers assay design, dosing logic, dendrimer-based delivery, and troubleshooting from cell culture through animal studies.

• KPT330 and Precision CRISPR-Cas9 Editing

  2026-08-25

  The reference study identifies selective inhibitors of nuclear export, particularly KPT330, as indirect regulators of Cas9, base-editor, and prime-editor activity. By limiting nuclear export of Cas9 mRNA rather than binding the Cas9 protein directly, this approach reduces excessive editing activity and improves precision in human-cell models.

7990 records 1/533 page Next 12345 下5页 Last page